Should I still hold IXHL

**Incannex Healthcare (IXHL) is a strong buy with a bullish outlook**, and here's why: 1. **Positive Clinical Trial Results**: IXHL has recently announced positive top-line Phase 2 results for its obstructive sleep apnea drug candidate, IHL-42X, with a substantial reduction in Apnea-Hypopnea Index (AHI) reported in the Phase 2/3 clinical trial. This development has generated considerable optimism among shareholders and could lead to increased investor confidence in the company's future prospects. 2. **Strategic Financing**: IXHL has secured strategic financing up to $60 million, which could provide the company with the necessary capital to support its clinical development and other operations. This financing could help the company to overcome potential financial hurdles and focus on its growth prospects. 3. **Joint Ventures and Partnerships**: IXHL has formed a joint venture with Mind Medicine Australia to expand access to psychedelic-assisted therapy, which could be a positive catalyst for the company's growth. This partnership could help the company to leverage the growing interest in psychedelic therapies and capitalize on the increasing demand for innovative mental health treatments. 4. **Market Sentiment**: Despite the recent volatility in the biotech sector, IXHL has shown resilience and positive momentum. The company's stock price has experienced a significant surge, which could be a sign of increasing investor confidence and a potential for further growth. 5. **Technical Indicators**: The stock's technical indicators are positive, with a strong buy signal from both short-term and long-term moving averages. The MACD and RSI suggest a bullish momentum, and the stock is currently in a strong buy position. In conclusion, IXHL's strong clinical pipeline, strategic financing, and positive market sentiment make it a strong candidate for holding. Investors should consider their investment goals and risk tolerance when deciding whether to buy or hold IXHL.